Clinical Trials Browser

Phase 1/2 × INDUSTRY × Daunorubicin × Clear all

NCT03850535 2022-06-21

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Phase 1/2 Terminated

24 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT02343939 2019-11-15

ENTO in AML

Phase 1/2 Terminated

148 enrolled 26 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00129168 2008-04-01

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute